Microbot Medical Inc. — filing identity warning
The supplied filing is not a Microbot Medical filing. It is StemCells, Inc.’s Form 10-K for the fiscal year ended December 31, 2013 (ticker STEM), filed in March 2014. The summary below describes the filing text, not Microbot Medical. The filing reports the full fiscal year; fourth-quarter figures are presented separately as unaudited quarterly data.
Business context and reporting period
StemCells was a development-stage stem-cell therapeutics and research-tools company. Its lead HuCNS-SC human neural stem-cell program was in clinical development for chronic spinal cord injury and dry age-related macular degeneration (AMD); the company also reported completed Phase I studies in Pelizaeus-Merzbacher disease and Batten disease, and preclinical work in Alzheimer’s disease. It sold research cell-culture products, cells, and reagents. No therapeutic product had received marketing approval.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $1.203 million | $1.368 million |
| Gross profit / gross margin | $0.887 million / approximately 73.7% | $1.105 million / approximately 80.8% |
| Research and development expense | $20.534 million | $15.847 million |
| General and administrative expense | $8.897 million | $7.447 million |
| Operating loss | $28.605 million | $22.546 million |
| Net loss | $26.439 million | $28.491 million |
| Basic and diluted loss per share | $0.61 | $0.99 |
| Cash and cash equivalents at year-end | $30.585 million | $8.471 million |
| Stockholders’ equity at year-end | $14.954 million | $13.985 million |
- Product sales were $0.998 million, up 17%; licensing, grants, and other revenue were $0.205 million, down 60%. Lower licensing revenue, including the absence of a prior-year one-time genOway fee, drove the total revenue decline.
- Operating cash use was about $23.3 million in 2013. The filing gives inconsistent figures: MD&A reports $23.286 million, while the cash-flow statement reports $23.322 million. Financing provided $36.402 million; investing provided $9.036 million, primarily from security maturities.
- Year-end total liabilities were $26.603 million. Loan payable, net of discount, was $12.909 million, including the Silicon Valley Bank loan and CIRM funding; the balance sheet also reported $5.542 million of warrant liabilities. The SVB loan bears 6% stated interest, includes a $1 million final payment, and is secured by substantially all assets other than intellectual property.
- Cash rose substantially following equity offerings, the SVB loan, and the initial CIRM disbursement. The filing nevertheless says existing resources might not fund operations beyond the next 12 months and that additional capital is required.
Material changes versus prior period
- Revenue decreased 12%, while operating expenses increased 25%, led by a 30% rise in R&D spending for clinical trials, personnel, preclinical work, and manufacturing and process development.
- Net loss narrowed from $28.491 million to $26.439 million, despite the larger operating loss. A $3.253 million gain from the change in fair value of warrant liabilities contributed to 2013 results; the comparable 2012 warrant remeasurement was a $5.945 million loss. This non-operating, valuation-driven item makes net-loss comparisons less indicative of operating performance.
- Cash and cash equivalents increased by $22.114 million. The company raised approximately $17.3 million net in an October public offering of units consisting of shares and warrants, among other financing activity. Shares outstanding increased from 37.5 million to 55.1 million during the year, and additional warrants and equity awards create potential dilution.
- The Rhode Island lease and related wind-down reserve ended in 2013, but the company still owned Rhode Island facilities and expected to pay approximately $137,000 in remaining bond principal and interest by July 2014.
Outlook, risks, contingencies, and unusual items
- Management expected to complete enrollment in the chronic spinal cord injury trial in Q1 2014 and the second AMD cohort by the end of Q2 2014. It planned controlled Phase II efficacy studies for cervical spinal cord injury and AMD during 2014. These were forward-looking plans, not assured outcomes.
- The filing stated that CIRM could provide up to approximately $19.3 million as a forgivable loan for Alzheimer’s preclinical and IND-enabling work, subject to milestones, covenants, and other conditions. The company reported receiving $3.8 million in July 2013 and another $3.8 million in January 2014; it targeted an Alzheimer’s IND filing by mid-2016.
- Management emphasized continuing losses, no expected profitability for several years, and reliance on future financing. A $100 million universal shelf registration was effective, but the filing warned that funds might not be available on acceptable terms and that programs could be delayed, scaled back, or stopped.
- Principal risks include dependence on one HuCNS-SC platform and early-stage trials; clinical, regulatory, manufacturing, reimbursement, and patient-enrollment uncertainty; competition; intellectual-property challenges; and dilution. The company disclosed ongoing patent litigation with Neuralstem; discovery was ongoing, and Neuralstem had appealed a European patent ruling.
- At year-end the company had $18.071 million in operating-lease commitments and $28.348 million in total listed contractual cash obligations, including loans and leases. The company reported no material off-balance-sheet arrangements beyond disclosed operating leases.
- Auditors issued an unqualified opinion on the financial statements. Management said disclosure controls and internal control over financial reporting were effective; the auditor did not express an opinion on internal-control effectiveness.
Fourth-quarter snapshot
For the quarter ended December 31, 2013, unaudited revenue was $313,000, operating expenses were $9.697 million, net loss was $6.962 million, and basic and diluted loss per share was $0.13. Other income, net, was $2.508 million, including the warrant-liability fair-value effect.
Most important facts for investors to verify
- Confirm the issuer and filing: this is StemCells, Inc.’s 2013 10-K, not Microbot Medical Inc.’s filing.
- Reconcile the reported operating cash outflow ($23.286 million in MD&A versus $23.322 million in the cash-flow statement) and assess cash burn against the company’s stated financing needs.
- Review the terms, repayment schedule, and conditions of the SVB and CIRM loans, including CIRM’s milestone-based and potentially forgivable structure.
- Assess trial progress and subsequent results against the stated 2014 enrollment and Phase II plans; early patient findings were preliminary and do not establish efficacy.
- Evaluate dilution from the 2013 share issuance, outstanding warrants, restricted stock units, and future financing requirements.
- Review the Neuralstem litigation, patent portfolio and expiration exposure, lease obligations, and other contractual commitments.